16 publications
Name | Date | Type | Actions |
---|---|---|---|
2024 half-year Results Sales: €264m (+3.2% as reported) |
Public releases | ||
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
Public releases | ||
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
Public releases | ||
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
Public releases | ||
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
Public releases | ||
Information relative au code de gouvernance Lors de la réunion du Conseil d’administration du 16 décembre 2014, les administrateurs ont adopté le code de gouvernance Middlenext. Depuis 2008, Vétoquinol se référait au code AFEP-MEDEF. |
Public releases | ||
Information relative au Code de Gouvernance (french) Lors de la réunion du Conseil d’administration du 16 décembre 2014, les |
Public releases | ||
Q3 2014 sales up 11.0% The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates). |
Public releases | ||
Solid growth in Q2 2014: 8.8% first half net income up 4.2% At its July 30, 2014 meeting, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first six months of 2014. |
Public releases | ||
Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction. |
Public releases |